15th Aug 2022 17:31
MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.
"Recreational cannabis consumption is implicated in as many as 13% of drivers involved in fatal road traffic accidents in Australia, yet the direct effect of medicinal cannabis use on driving performance remains unclear. Legislative changes in Australia permit the regulated consumption of cannabinoid-based products for therapeutic purposes, however, currently there is no standard clinical or legal guidance outlining when it is safe to drive after its use, and a positive roadside saliva test for THC may lead to criminal convictions irrespective of prescribed use," MGC explains.
"It is hoped that standardised assessment of performance decrements, such of the findings of this trial, will inform policy guidelines concerning responsible use of medicinal cannabis products."
Current stock price: 1.10 pence, up 7.3% on Monday in London
12-month change: down 51%
By Elizabeth Winter; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
MXC.L